-
公开(公告)号：US09108970B2
公开(公告)日：2015-08-18
申请号：US13886032
申请日：2013-05-02
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher , Zhe Nie
IPC: C07D471/04 , A61K31/437 , A61P11/06 , A61P35/00 , A61P17/06 , A61P29/00 , A61P11/08 , A61P37/02 , A61K31/527 , A61K45/06 , C07D487/10 , C07D519/00 , C07D487/04 , A61K31/519
CPC classification number: C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。
-
公开(公告)号：US20180186772A1
公开(公告)日：2018-07-05
申请号：US15909801
申请日：2018-03-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/14 , A61K31/496 , C07D487/06 , A61K31/4985 , A61K31/5513 , C07D491/107 , C07D405/14 , C07D471/08 , C07D401/04 , A61K31/4545 , C07D487/10 , A61K31/444 , A61K31/551 , C07D491/10 , A61K31/5377 , C07D417/14 , C07D413/14 , C07D487/04
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
公开(公告)号：US20200277262A1
公开(公告)日：2020-09-03
申请号：US16650858
申请日：2018-09-24
Applicant: Benjamin Jones , Andre Kiryanov , Jon Kuehler , Marion Lanier , Sean Murphy , Feng Zhou , Takeda Pharmaceutical Company Limited
Inventor： Benjamin Jones , Andre Kiryanov , Jon Kuehler , Marion Lanier , Sean Murphy , Feng Zhou
IPC: C07D213/81
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, R7, R8, R9, X1 and X2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with PHD.
-
公开(公告)号：US09944626B2
公开(公告)日：2018-04-17
申请号：US15620620
申请日：2017-06-12
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D413/14 , A61K31/5377 , C07D401/14 , C07D487/06 , C07D417/14 , C07D491/10 , A61K31/551 , A61K31/444 , C07D487/10 , A61K31/4545 , C07D401/04 , C07D471/08 , C07D405/14 , C07D491/107 , A61K31/5513 , A61K31/4985 , C07D487/04 , A61K31/496
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
公开(公告)号：US20170275271A1
公开(公告)日：2017-09-28
申请号：US15620620
申请日：2017-06-12
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/14 , A61K31/496 , C07D417/14 , A61K31/5377 , C07D491/10 , A61K31/551 , A61K31/444 , C07D487/10 , A61K31/4545 , C07D401/04 , C07D471/08 , C07D405/14 , C07D491/107 , A61K31/5513 , A61K31/4985 , C07D487/04 , C07D487/06 , C07D413/14
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
Patent Agency Ranking
公开(公告)号：US20160251337A1
公开(公告)日：2016-09-01
申请号：US15150976
申请日：2016-05-10
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/14 , C07D413/14 , C07D401/04 , C07D471/08 , C07D491/107 , C07D487/04 , C07D487/10 , C07D405/14 , C07D417/14
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
Abstract translation: 本发明提供下式的化合物：其可用作PHD的抑制剂，其药物组合物，用于治疗与HIF相关的病症的方法，用于制备化合物的方法及其中间体。
-
公开(公告)号：US09345713B2
公开(公告)日：2016-05-24
申请号：US14693110
申请日：2015-04-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: A61K31/496 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D491/107 , C07D417/14 , C07D471/08 , C07D487/06 , C07D487/10 , C07D491/10 , A61K31/444 , A61K31/4545 , A61K31/4985 , A61K31/5377
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides a method of treating acute heart failure by administering a compound of the formula: or a pharmaceutically acceptable salt thereof.
Abstract translation: 本发明提供了通过给予下式化合物或其药学上可接受的盐治疗急性心力衰竭的方法。
-
公开(公告)号：US20150336964A1
公开(公告)日：2015-11-26
申请号：US14814878
申请日：2015-07-31
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Yasuyoshi Arikawa , Benjamin Jones , Betty Lam , Christopher Smith , Masashi Takahashi , Qing Dong , Victoria Feher , Zhe Nie
IPC: C07D487/04 , A61K45/06 , A61K31/527 , A61K31/437 , C07D487/10 , A61K31/519 , C07D471/04
CPC classification number: C07D487/04 , A61K31/437 , A61K31/519 , A61K31/527 , A61K45/06 , C07D471/04 , C07D487/10 , C07D519/00
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中G，L1，L2，R1，R2，R3和R4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗涉及免疫系统和炎症的疾病，疾病和病症的用途，包括类风湿性关节炎，血液恶性肿瘤，上皮癌（即， 癌症）以及其它疾病，疾病和表示SYK抑制的病症。
-
9.发明授权公开(公告)号：US11426397B2
公开(公告)日：2022-08-30
申请号：US16497967
申请日：2018-03-26
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Jason Green , Maria Hopkins , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Holger Monenschein , Sean Murphy , Thomas Nixey , Huikai Sun
IPC: C07D417/12 , A61K31/4545 , A61K31/198 , A61K31/451 , A61K31/4525 , A61K31/4535 , A61K31/454 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5365 , A61K31/553 , C07D211/52 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D487/04 , C07D498/04
Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
-
公开(公告)号：US10407409B2
公开(公告)日：2019-09-10
申请号：US15909801
申请日：2018-03-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K31/496 , A61K31/551 , C07D491/107 , C07D471/08 , C07D487/06 , C07D487/10 , C07D491/10 , A61K31/444 , A61K31/4985 , A61K31/5513 , C07D487/04
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.042 seconds)
